Table 3.
Antimicrobial screening results of the synthesized 1,2,4-triazole derivatives (T1–T20)
| Compound | Minimum inhibitory concentration (µM) | ||||
|---|---|---|---|---|---|
| Bacterial strain | Fungal strain | ||||
| Gram +ve | Gram −ve | ||||
| B. substilis | P. aeruginosa | E. coli | C. albican | A. niger | |
| T1 | 120.5 | 241.1 | 241.1 | 241.1 | 120.5 |
| T2 | 56.4 | 56.4 | 112.9 | 225.9 | 225.9 |
| T3 | 58.3 | 58.3 | 116.6 | 233.2 | 116.6 |
| T4 | 52.6 | 52.6 | 105.3 | 52.6 | 105.3 |
| T5 | 24.7 | 12.3 | 24.7 | 12.3 | 99.0 |
| T6 | 108.5 | 54.2 | 54.2 | 108.5 | 217.0 |
| T7 | 116.1 | 29.0 | 116.1 | 232.2 | 232.2 |
| T8 | 116.1 | 58.0 | 58.0 | 116.1 | 232.2 |
| T9 | 54.6 | 27.3 | 54.6 | 109.2 | 218.4 |
| T10 | 55.6 | 55.6 | 111.3 | 222.6 | 55.6 |
| T11 | 55.6 | 111.3 | 111.3 | 27.8 | 111.3 |
| T12 | 103.4 | 51.7 | 103.4 | 206.8 | 103.4 |
| T13 | 101.3 | 202.6 | 202.6 | 101.3 | 202.6 |
| T14 | 50.6 | 101.3 | 101.3 | 202.6 | 101.3 |
| T15 | 54.3 | 108.7 | 217.5 | 217.5 | 54.3 |
| T16 | 108.7 | 108.7 | 217.5 | 217.5 | 217.5 |
| T17 | 54.3 | 217.5 | 217.5 | 108.7 | 27.1 |
| T18 | 104.0 | 52.0 | 104.0 | 208.0 | 104.0 |
| T19 | 113.4 | 226.9 | 56.7 | 113.4 | 113.4 |
| T20 | 61.7 | 123.5 | 61.7 | 247.1 | 247.1 |
| Fluconazole | – | – | – | 40.8 | 20.4 |
| Ciprofloxacin | 18.0 | 18.0 | 37.7 | – | – |
| Amoxicillin | 17.1 | 17.1 | 17.1 | – | – |
Italics signifies the most active compound in comparison to the standard compound